About me
Ben Ackerman is a Director of Real-world Biostatistics at GSK, where he designs and analyzes real-world evidence studies in oncology. He has expertise in causal inference methods to address various biases in both randomized trials and non-experimental studies. Previously, he led a research team at J&J to develop novel methods for quantifying and mitigating bias due to endpoint measurement differences when conducting external control arm analyses. Ben holds a PhD in Biostatistics from the Johns Hopkins Bloomberg School of Public Health.
